Literature DB >> 6538019

HLA antigens in Guillain-Barré syndrome.

R A Kaslow, J Z Sullivan-Bolyai, B Hafkin, L B Schonberger, L Kraus, M J Moore, E Yunis, R M Williams.   

Abstract

We compared Guillain-Barré syndrome (GBS) cases reported from cities in the United States in 1976-1977 with spouse or associate controls to detect possible HLA associations. HLA-A11 was somewhat less common among 92 cases than among 100 controls (p = 0.04). The 38 patients and 42 controls vaccinated against A/NJ/76 differed slightly in overall distribution of B locus antigens (p = 0.06), but the individual HLA-B antigen associations were more easily explained by chance. The 54 unvaccinated cases showed no apparent relation to HLA type. These findings should encourage further immunogenetic study of etiologically related GBS cases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538019     DOI: 10.1212/wnl.34.2.240

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Higher frequencies of HLA DQB1*05:01 and anti-glycosphingolipid antibodies in a cluster of severe Guillain-Barré syndrome.

Authors:  L Schirmer; V Worthington; U Solloch; V Loleit; V Grummel; N Lakdawala; D Grant; R Wassmuth; A H Schmidt; F Gebhardt; T F M Andlauer; J Sauter; A Berthele; M P Lunn; Bernhard Hemmer
Journal:  J Neurol       Date:  2016-08-02       Impact factor: 4.849

2.  Guillain-barré syndrome following influenza vaccination: causal or coincidental?

Authors:  James J Sejvar; Dina Pfeifer; Lawrence B Schonberger
Journal:  Curr Infect Dis Rep       Date:  2011-08       Impact factor: 3.725

Review 3.  Guillain-Barré syndrome, transverse myelitis and infectious diseases.

Authors:  Yhojan Rodríguez; Manuel Rojas; Yovana Pacheco; Yeny Acosta-Ampudia; Carolina Ramírez-Santana; Diana M Monsalve; M Eric Gershwin; Juan-Manuel Anaya
Journal:  Cell Mol Immunol       Date:  2018-01-29       Impact factor: 11.530

Review 4.  Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.

Authors:  Eroboghene E Ubogu
Journal:  Acta Neuropathol       Date:  2015-08-12       Impact factor: 17.088

Review 5.  Enhancing vaccine safety capacity globally: A lifecycle perspective.

Authors:  Robert T Chen; Tom T Shimabukuro; David B Martin; Patrick L F Zuber; Daniel M Weibel; Miriam Sturkenboom
Journal:  Vaccine       Date:  2015-10-01       Impact factor: 3.641

Review 6.  Vaccines and Guillain-Barré syndrome.

Authors:  Penina Haber; James Sejvar; Yann Mikaeloff; Frank DeStefano
Journal:  Drug Saf       Date:  2009       Impact factor: 5.228

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.